Company: ARTL
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001640334-25-001429
Chunk: 386

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 386
---
PART I - FINANCIAL INFORMATION

ARTELO BIOSCIENCES, INC.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

   June 30,    December 31,    2025  2024        ASSETS      Current Assets      Cash and cash equivalents $2,066  $2,338 Prepaid expenses and other current assets  167   219 Total Current Assets  2,233   2,557 Operating lease right-of-use assets  82   99 Intangible asset  2,039   2,039 Other assets  3   3 TOTAL ASSETS $4,357  $4,698          LIABILITIES AND STOCKHOLDERS' EQUITY        Current Liabilities        Accounts payable and accrued liabilities $4,841  $1,676 Accrued interest – convertible notes  18   - Due to related parties  26   61 Operating lease liabilities - current portion  36   35 Convertible notes  791   - Total Current Liabilities  5,712   1,772          Operating lease liabilities  51   69 TOTAL LIABILITIES  5,763   1,841          STOCKHOLDERS' EQUITY        Preferred Stock, par value $0.001, 69,445 shares authorized, 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024  -   - Common Stock, par value $0.001, 8,333,333 shares authorized and 704,425 and 567,582 shares issued and outstanding as of June 30, 2025, and December 31, 2024, respectively  1   1 Additional paid-in capital  54,617   53,194 Accumulated deficit  (55,729)  (50,136)Accumulated other comprehensive loss   (295)  (202)TOTAL STOCKHOLDERS' (DEFICIT) EQUITY  (1,406)  2,857          TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $4,357  $4,698